Pharma News

Researchers have identified four promising blood-based metabolites that may help distinguish individuals with latent tuberculosis infection (LTBI) from those without infection, according to a new study published in BIO Integration. The findings provide fresh insights into the metabolic changes associated with latent tuberculosis and could support the development of improved diagnostic approaches in the future.

Bharat Biotech's plans to advance its tuberculosis vaccine candidate MTBVAC (BBV169) into Phase III clinical trials have been put on hold after the Subject Expert Committee (SEC) on Vaccines sought additional data and protocol revisions before granting further approval.

The proposal was reviewed during the meeting of the SEC - Vaccine held on May 28, 2026. The company presented its Phase III clinical trial protocol along with an interim report from the ongoing Phase II clinical study.

India’s drug regulator has issued a fresh reminder to pharmaceutical manufacturers and other stakeholders regarding the mandatory implementation of pharmacovigilance (PV) systems under the provisions of the Drugs and Cosmetics Act, 1940 and related rules.

Glenmark Pharmaceuticals Ltd. has announced that its U.S.-based subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Lacosamide Injection USP 200 mg/20 mL (10 mg/mL) Single-Dose Vials in the United States market. The product is the generic equivalent of Vimpat Injection marketed by UCB Inc. and is indicated for the treatment of seizures associated with epilepsy.

New research presented at the annual Congress of the European Alliance of Associations for Rheumatology (EULAR) suggests that continuing urate-lowering therapy (ULT) remains the most effective strategy for maintaining remission in patients with gout, although some patients may successfully remain symptom-free after discontinuing treatment.

In a move aimed at improving access to diabetes and obesity treatment, Alkem Laboratories has launched India's first semaglutide single-shot pre-filled syringes, with prices starting at just ₹350.

The launch marks another milestone in the rapidly evolving obesity and diabetes care market, as Alkem continues to expand its semaglutide portfolio following the introduction of pre-filled disposable and reusable injection pens earlier this year.